Hbl- Hadasit Bio-holdings Ltd. · TASE:HDST-M
Hbl- Hadasit Bio-holdings — Hadasit Bio-Holdings — Investor Presentation (July 2008)
23 slides from Hbl- Hadasit Bio-holdings's investor presentation, July 2008
Slide 1: Hadasit Bio-Holdings Ltd. – HBL
Hadasit Bio-Holdings Ltd. – “HBL” ((Tel Aviv Stock Exchange: HDST July 2008
Slide 2: Forward Looking Statements
Forward Looking Statements This document/presentation contains forward looking statements. Words such as “estimates,” “expects,” “intends,” “plans,” “believes” and terms of similar substance used in connection with any discussion of future operational performance or financial results, identify forwa
Slide 3: The Value Chain in Israeli Biotech
July 2008 The Value Chain in Israeli Biotech Strategic Partnering Specialized Public Academy Govt. Angels Incubation Clustering Investment & TTO’s Support & VC’s Co. Yeda Meytav OCS Bioline Ofer HT BioLight Yissum Rad-BIO Magnet Biomedix Glenrock Clal Bio Ramot Naiot BIRD HMO Bio- Coronis Maayan BG
Slide 4: HBL - Company Profile
HBL - Company Profile Holdings in early-stage biotech companies (until completion of Phase I) • 10 companies – All IP developed at Hadassah • 3 areas (Oncology, Auto-immune diseases, Tissue engineering / Stem cells) • Criteria – Demonstration of Proof of Concept, Blockbuster Market • Exit strategy -
Slide 5: HBL Structure (7/08)
HBL Structure (7/08) 100% Drug Engineering Public 43% 52% ConjuGate 30% C.B.G 5% H.B.L Ltd. 22% 66% 25% 34% 4.5% 75% 100% 80% 92% Forticell Thrombo Bio. Verto ProtAb KAHR Tolarex Incure TK Signal Cell Cure tech (UK) (Nasdaq) Oncology Tissue Engineering Auto-immune Disease and Stem-cell Medicine
Slide 6: 4 Key Building Blocks – F.I.M.S
4 Key Building Blocks – “F.I.M.S” Finance .I.P .Mgt Space IPO Hadassah Experienced “Bio-Park”: Managers Bond new 50 6 floors of Patents per All HMO 1,500 m2 o PIPE - CBG year Experts Fully OCS Partnering Seasoned customized for Venture Pharma + Biotech .Heb.U Philanthropy VC Execs. companies U.PENN
Slide 7: 2008 – Value Adding Milestones
2008 – Value Adding Milestones KAHR – HBL Investment, 5 New Compounds from UPENN, OCS approval for $ 400 K, new VP, external investment Tolarex – HBL Investment, IND approval from FDA, Phase I start, external investment ProtAb – Completion of humanization – external investment TK Signal – Pr
Slide 8: Hadassah Bio-Park - 2008
Hadassah Bio-Park - 2008 First medical center “on-site” bio park – custom built for life science companies (including labs,Phase I center) Building upon infrastructure of Hebrew U. Med. School and Hadassah University Hospital (conducting more than 50% of all translational medicine research in Is
Slide 9: Investment Strategy
Investment Strategy High return on investment through investments before the 1 first clinical phase (Phase I) – After proof of concept in animals and before completion of Phase I – Value multipliers: X 10 to X 50 – Midway Exit planned after Phase I, clear dividend policy Product target markets m
Slide 10: Focus - Return on Investment
1 Focus - Return on Investment ”HBL’s “Sweet Spot At Phase I Highest rate of success Increase in value of vis-à-vis required 10x to 30x investment required % investment Approval Odds that company will advance from this phase to the next Percent of total investment Required investment $m Years 10
Slide 11: The Biggest Growth in Value Has Been at Clinical Proof of Concept
The Biggest Growth in Value Has Been at Clinical Proof of Concept Upfront only (No milestones Phase I/II Deals or royalties) – Ave. of 35 M $700 20 18 $600 $ Upfront Total No. of Deals 16 $500 14 No. of Transactions 12 $ Millions $400 10 $300 8 $200 6 4 $100 2 $0 0 2001 2002 2003 2004 2005 2006 SOUR
Slide 12: Market
Unmet clinical needs Market size in 2 Market billions Size Market Size Field/Treating Company Stroke – US$ 500 mm; Thrombosis, Myocardial Thrombotech Cardiac Arrest – US$ 1 billion Infarction Systemic infections – US$ 6 billion Drug Reformulation – Systemic ConjuGate infections Cancer + Autoimmune d
Slide 13: Management
Management Dr. Rafi Hofstein - Chairman of the Board. President and CEO of Hadasit Ltd., the Technology Holdings Company of Hadassah Medical Organization. Ex-President of Mindsense Biosystems Ltd. Business Unit Director of Ecogen Inc., Langhorne PA after serving as the Scientific Director of its Isr
Slide 14: Board of Directors / Advisory Board
Board of Directors / Advisory Board Prof. Shlomo Mor-Yosef, HMO Director General Yuval Cohen, Fortissimo Private Equity Doron Debbie (Consensus Business Group) Tsipi Gal-Yam (External) Yaron Kulas (External) Prof. Ruth Arnon (Weizmann) Steven G. Burrill – Burrill & Co. Tamar Howson (
Slide 15: External Investments in Companies
External Investments in Companies 2 Major Strategic Investors / Partners have Invested in HBL Portfolio Companies, : TEVA Pharmaceutical Industries - $ 1 M in Cell Cure NeuroSciences (Aug. 2007) – Recognition of leadership in HESC field – Attractive terms for company (value, rights) – Significant
Slide 16: HBL Product Pipeline
HBL Product Pipeline (7/08) Company Product Indication Discovery Lead Efficacy in IND Phase Phase Pha. Phase Selection Animal Prep. I I / II II III Models PMA Verto Luposorb Lupus Done Tolarex ApoCell Graft Vs. Host Disease TK Signal Fenol Multiple Dopam Myeloma ProtAb AP6 Reum. Arth. Inf. B. Diseas
Slide 17: Progress in Portfolio Companies (I)
Progress in Portfolio Companies (I) Cell Cure NeuroSciences • Investment agreement with TEVA ($ 1 M at $ 13 pre-$) • HBL holdings increased to 34.5% • All IP related to Neurological Disorders (Parkinson, MS, Alzheimer’s) – permanently released and owned by the company • Receipt of $ 2 M in "soft fun
Slide 18: Progress in Portfolio Companies (II)
Progress in Portfolio Companies (II) ProtAb (PTK) • Humanization and production of the lead antibody underway (Antitope – Cambridge, UK). First samples arrived and tested. • OCS approved 60% of R&D budget ($ 500 K). • Discussions with private and VC investors. • Significant interest from strategic p
Slide 19: Progress in Portfolio Companies (III)
Progress in Portfolio Companies (III) Tolarex (PTK) • Advanced preparations for clinical trial – Q1/08, Passed IRB, awaiting MOH approval and pre-IND at the FDA • Additions of personnel (7) and equipment. OCS approved R&D budget of $ 1.1 M (60% support) • CEO – experience in drug development (Alon M
Slide 20: Progress in Portfolio Companies (IV)
Progress in Portfolio Companies (IV) Incure • Expansion of ELISA study – 40 patients. Groups added: elders, smokers, pregnant. • Data showing detection of cancer metastases via blood sample. • Negotiation with US strategic partner – licensing & financing deal. • Next step – commercialization via des
Slide 21: Financial Data
Financial Data $ 3.0 in cash, as of 1/6/08 3 Leading companies (PTK) raising between $ 3-5 M each All companies show major progress since HBL Investment Timeline: 3 companies in Phase I within 12-18 months Pipeline Potential: exclusive mandate (“first look”) for IP from 1,200 MD’s/PhD’s at
Slide 22: Summary
Summary All companies are funded by HBL, partners Leverage of “soft funds”: OCS, research foundations Science, IP and Infrastructure – HMO Key milestone events expected (Phase I, analyst coverage and external investment) Validation of strategic model via external strategic investors (CBG,
Slide 23: Thank You
Thank You Ophir Shahaf, CEO Hadasit Bio-Holdings Ltd. Tel.: +972-54-520-1177 23
Hadasit Bio-Holdings — Investor Presentation (July 2008) on 6ix